上海醫藥(02607.HK)風濕性疾病及免疫藥物獲批臨床試驗

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

上海醫藥(02607.HK)風濕性疾病及免疫藥物獲批臨床試驗

阿思達克 05-30 17:02

上海醫藥(02607.HK)公布，全資子公司上藥技創開發的風濕性疾病及免疫藥物「塞來昔布膠囊(I)」收到國家藥監局核准簽發的《藥物臨床試驗批准通知書》，將於近期啟動改良型新藥的臨床試驗。

上海醫藥(02607.HK)

Relevant Stocks

上海醫藥(02607.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

上海醫藥(02607.HK)風濕性疾病及免疫藥物獲批臨床試驗

Services

About Us

Agreement Statement